Literature DB >> 20237128

Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.

Stéphane Thobois1, Claire Ardouin, Eugénie Lhommée, Hélène Klinger, Christelle Lagrange, Jing Xie, Valérie Fraix, Maria Clara Coelho Braga, Rachid Hassani, Andrea Kistner, Alexandra Juphard, Eric Seigneuret, Stephan Chabardes, Patrick Mertens, Gustavo Polo, Anthonin Reilhac, Nicolas Costes, Didier LeBars, Marc Savasta, Léon Tremblay, Jean-Louis Quesada, Jean-Luc Bosson, Alim-Louis Benabid, Emmanuel Broussolle, Pierre Pollak, Paul Krack.   

Abstract

Apathy has been reported to occur after subthalamic nucleus stimulation, a treatment of motor complications in advanced Parkinson's disease. We carried out a prospective study of the occurrence of apathy and associated symptoms, predictors and mechanisms in the year following subthalamic stimulation. Dopamine agonist drugs were discontinued immediately after surgery and levodopa was markedly reduced within 2 weeks. Apathy and depression were assessed monthly, using the Starkstein apathy scale and the Beck Depression Inventory. Dopamine agonists were re-introduced if patients developed apathy or depression. Preoperative non-motor fluctuations were evaluated using the Ardouin Scale. Depression, apathy and anxiety were evaluated both on and off levodopa. Analysis of predictors of apathy was performed using a Cox proportional hazard model. Twelve patients who developed apathy and a control group of 13 patients who did not underwent [11C]-raclopride positron emission tomography scanning before and after oral intake of methylphenidate. In 63 patients with Parkinson's disease treated with subthalamic stimulation, dopaminergic treatment was decreased by 82% after surgery. Apathy occurred after a mean of 4.7 (3.3-8.2) months in 34 patients and was reversible in half of these by the 12-month follow-up. Seventeen patients developed transient depression after 5.7 (4.7-9.3) months and these fell into the apathy group with one single exception. At baseline, fluctuations in depression, apathy and anxiety scores were greater in the group with apathy. Fluctuations in apathy, depression and anxiety ratings during a baseline levodopa challenge were also significant predictors of postoperative apathy in univariate analysis, but not motor and cognitive states or the level of reduction of dopaminergic medication. The multivariate model identified non-motor fluctuations in everyday life and anxiety score during the baseline levodopa challenge as two independent significant predictors of postoperative apathy. Without methylphenidate, [11C]-raclopride binding potential values were greater in apathetic patients bilaterally in the orbitofrontal, dorsolateral prefrontal, posterior cingulate and temporal cortices, left striatum and right amygdala, reflecting greater dopamine D2/D3 receptor density and/or reduced synaptic dopamine level in these areas. The variations of [11C]-raclopride binding potential values induced by methylphenidate were greater in non-apathetic patients in the left orbitofrontal cortex, dorsolateral prefrontal cortex, thalamus and internal globus pallidus and bilaterally in the anterior and posterior cingulate cortices, consistent with a more important capacity to release dopamine. Non-motor fluctuations are related to mesolimbic dopaminergic denervation. Apathy, depression and anxiety can occur after surgery as a delayed dopamine withdrawal syndrome. A varying extent of mesolimbic dopaminergic denervation and differences in dopaminergic treatment largely determine mood, anxiety and motivation in patients with Parkinson's disease, contributing to different non-motor phenotypes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237128     DOI: 10.1093/brain/awq032

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  120 in total

1.  Apathy and depression: separate factors in Parkinson's disease.

Authors:  Lindsey Kirsch-Darrow; Michael Marsiske; Michael S Okun; Russell Bauer; Dawn Bowers
Journal:  J Int Neuropsychol Soc       Date:  2011-11       Impact factor: 2.892

Review 2.  High frequency deep brain stimulation of the subthalamic nucleus versus continuous subcutaneous apomorphine infusion therapy: a review.

Authors:  R Carron; V Fraix; C Maineri; E Seigneuret; B Piallat; P Krack; P Pollak; A L Benabid; Stéphan Chabardès
Journal:  J Neural Transm (Vienna)       Date:  2010-12-29       Impact factor: 3.575

3.  Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?

Authors:  Rupam Borgohain; Rukmini Mridula Kandadai; Afshan Jabeen; Meena A Kannikannan
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

4.  A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation.

Authors:  Angelo Antonini; Ioannis U Isaias; Giorgia Rodolfi; Andrea Landi; Francesca Natuzzi; Chiara Siri; Gianni Pezzoli
Journal:  J Neurol       Date:  2010-10-23       Impact factor: 4.849

Review 5.  Parkinson's disease: the quintessential neuropsychiatric disorder.

Authors:  Daniel Weintraub; David J Burn
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

Review 6.  Movement disorders in 2010: Parkinson disease-symptoms and treatments.

Authors:  Marie Vidailhet
Journal:  Nat Rev Neurol       Date:  2011-02       Impact factor: 42.937

7.  Motivational modes and learning in Parkinson's disease.

Authors:  Karin Foerde; Erin Kendall Braun; E Tory Higgins; Daphna Shohamy
Journal:  Soc Cogn Affect Neurosci       Date:  2014-12-30       Impact factor: 3.436

Review 8.  Current Practice and the Future of Deep Brain Stimulation Therapy in Parkinson's Disease.

Authors:  Leonardo Almeida; Wissam Deeb; Chauncey Spears; Enrico Opri; Rene Molina; Daniel Martinez-Ramirez; Aysegul Gunduz; Christopher W Hess; Michael S Okun
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

9.  STN vs. GPi Deep Brain Stimulation: Translating the Rematch into Clinical Practice.

Authors:  Nolan R Williams; Kelly D Foote; Michael S Okun
Journal:  Mov Disord Clin Pract       Date:  2014-04-01

10.  [Deep brain stimulation for Parkinson's disease: timing and patient selection].

Authors:  R Erasmi; G Deuschl; K Witt
Journal:  Nervenarzt       Date:  2014-02       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.